Workboat Indexes

Ucb S.A. (OP: UCBJF )

195.90 UNCHANGED

Streaming Delayed Price Updated: 9:59 AM EST, Dec 19, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	195.90
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	195.90
Today's Range	195.90 - 195.90
52wk Range	87.10 - 195.90
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

November 20, 2024

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Via Benzinga

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

November 20, 2024

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.

Via Benzinga

Performance

YTD	+95.90%	+95.90%
1 Month	+0.01%	+0.01%
3 Month	+6.47%	+6.47%
6 Month	+30.73%	+30.73%
1 Year	+124.91%	+124.91%

More News

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

September 24, 2024

Via Benzinga

Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage

September 10, 2024

Via Benzinga

Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB

August 29, 2024

Via Benzinga

UCB's Rare Childhood Epilepsy Drug Scores FDA Approval

March 28, 2022

Via Benzinga

Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies

August 26, 2024

Via Benzinga

There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target

January 02, 2024

Via Benzinga

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst

September 28, 2023

Via Benzinga

Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts

August 31, 2023

Via Benzinga

FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults

June 27, 2023

Via Benzinga

Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path

February 14, 2023

Via Benzinga

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

February 08, 2022

Via Benzinga

UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study

January 21, 2022

Via Benzinga

UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights

January 19, 2022

Via Benzinga

UCB Gets EU Approval For Bimekizumab In Psoriasis

August 25, 2021

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.